In vitro compatibility study of cephalosporin with intraocular irrigating solutions and intracameral medications

Clinical and Experimental Ophthalmology

Volumn 39, Issue 2, 2011, Pages 164-170

  Hui, Mamie ^a   Lam, Philip T H ^b   Cheung, Siu Wai ^a   Pang, Chi Pui ^b   Chan, Chiu Yeung ^a   Lam, Dennis S ^b  

^a Departments of Microbiology   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Balanced salt solution; Cefazolin; Ceftazidime; Cefuroxime; Endophthalmitis

Indexed keywords

ACETYLCHOLINE; ADRENALIN; BALANCED SALT SOLUTION; CARBACHOL; CEFTAZIDIME; CEFTEZOLE; CEFUROXIME; RINGER SOLUTION; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ZINCEF;

ARTICLE; CATARACT EXTRACTION; CONTROLLED STUDY; EYE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION;

ACETATES; ACETYLCHOLINE; ANTI-BACTERIAL AGENTS; BACTERIA; BIOLOGICAL AVAILABILITY; CARBACHOL; CEFAZOLIN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; DRUG INCOMPATIBILITY; DRUG INTERACTIONS; EPINEPHRINE; MICROBIAL SENSITIVITY TESTS; MINERALS; OPHTHALMIC SOLUTIONS; SODIUM CHLORIDE; THERAPEUTIC IRRIGATION;

EID: 79952677063     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02402.x     Document Type: Article

References (45)

1. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991; 98: 639-50.
2. Samad A, Solomon LD, Miller MA, Mendelson J. Anterior chamber contamination after uncomplicated phacoemulsification and intraocular lens implantation. Am J Ophthalmol 1995; 120: 143-50.
3. Mistlberger A, Ruckhofer J, Raithel E etal. Anterior chamber contamination during cataract surgery with intraocular lens implantation. J Cataract Refract Surg 1997; 23: 1064-9.
4. John T, Sims M, Hoffmann C. Intraocular bacterial contamination during sutureless, small incision, single-port phacoemulsification. J Cataract Refract Surg 2000; 26: 1786-91.
5. Leong JK, Shah R, McCluskey PJ, Benn RA, Taylor RF. Bacterial contamination of the anterior chamber during phacoemulsification cataract surgery. J Cataract Refract Surg 2002; 28: 826-33.
6. Parmar P, Kaliamurthy J, Prasanth DA, Thomas PA, Jesudasan CA. Anterior chamber contamination during phacoemulsification and manual small-incision cataract surgery. Am J Ophthalmol 2006; 141: 1160-1.
7. Bausz M, Fodor E, Resch MD, Kristóf K. Bacterial contamination in the anterior chamber after povidone-iodine application and the effect of the lens implantation device. J Cataract Refract Surg 2006; 32: 1961-5.
8. Ta CN, Singh K, Egbert PR, de Kaspar HM. Prospective comparative evaluation of povidone-iodine (10% for 5 minutes versus 5% for 1 minute) as prophylaxis for ophthalmic surgery. J Cataract Refract Surg 2008; 34: 171-2.
9. Ta CN, Sinnar S, He L, Myung D, de Kaspar HM. Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. Eur J Ophthalmol 2007; 17: 689-95.
10. Garat M, Moser CL, Alonso-Tarres C etal. Intracameral cefazolin to prevent endophthalmitis in cataract surgery: 3-year retrospective study. J Cataract Refract Surg 2005; 31: 2230-4.
11. Romero P, Mendez I, Salvat M etal. Intracameral cefazolin as prophylaxis against endophthalmitis in cataract surgery. J Cataract Refract Surg 2006; 32: 438-41.
12. Montan PG, Wejde G, Koranyi G, Rylander M. Prophylactic intracameral cefuroxime - efficacy in preventing endophthalmitis after cataract surgery. J Cataract Refract Surg 2002; 28: 977-81.
13. García-Sáenz MC, Arias-Puente A, Rodriguez-Caravaca G, Bañuelos JB. Effectiveness of intracameral cefuroxime in preventing endophthalmitis after cataract surgery: ten-year comparative study. J Cataract Refract Surg 2010; 36: 203-7.
14. ESCRS Endophthalmitis Study Group. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007; 33: 978-88.
15. Corbett MC, Richards AB. Intraocular adrenaline maintains mydriasis during cataract surgery. Br J Ophthalmol 1994; 78: 95-8.
16. Catford GV, Millis E. Clinical experience in the intra-ocular use of acetylcholine. Br J Ophthalmol 1967; 15: 183-7.
17. Yee RW, Edelhauser HF. Comparison of intraocular acetylcholine and carbachol. J Cataract Refract Surg 1986; 12: 18-22.
18. Solomon KD, Stewart WC, Hunt HH etal. Intraoperative intracameral carbachol in phacoemulsification and posterior lens implantation. Am J Ophthalmol 1998; 125: 36-43.
19. Kwok AKH, Hui M, Pang CP etal. An in vitro study of ceftazidime and vancomycin concentrations in various fluid media: implications for use in treating endophthalmitis. Invest Ophthalmol Vis Sci 2002; 43: 1182-8.
20. Bron AJ, Tripathi RC, Tripathi BJ. Wolff's Anatomy of the Eye and Orbit, 8th edn. London: Chapman & Hall, 1997.
21. Chan CY, Chan K, French GL. Rapid high-performance liquid chromatographic assay of cephalosporins in biological fluids. J Antimicrob Chemother 1986; 18: 537-45.
22. Sweetman S, ed. Martindale - The Complete Drug Reference. London: Pharmaceutical Press, (electronic version) Thomson Micromedex, Greenwood Colorado, USA. Accessed November 2009. Available from.
23. Lockington D, Flowers H, Young D, Yorston D. Assessing the accuracy of intracameral antibiotic preparation for use in cataract surgery. J Cataract Refract Surg 2010; 36: 286-9.
24. Ryan TP. Statistical Methods for Quality Improvement, 2nd edn. New York: Wiley, 2000.
25. VCCLAB, Virtual Computational Chemistry Laboratory. 2005. Accessed Jun 2010. Available from.
26. Product insert M26491. Zinacef: cefuroxime sodium for injection. Glaxo, Greenford, UK. Nov 1985.
27. Ravaoarinoro M, Therrien C. Comparative in vitro activity of nine antistaphylococcal agents against 275 recent isolates of Gram-positive cocci. Int J Antimicrob Agents 1996; 7: 167-70.
28. Song HK, Oh JI, Kim MY etal. In-vitro and in-vivo antibacterial activity of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum. J Antimicrob Chemother 1996; 37: 711-26.
29. Hoban DJ, Bouchillon SK, Johnson JL etal. Surveillance Study Research Group. Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study. Int J Antimicrob Agents 2003; 21: 425-33.
30. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210-19.
31. Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn Microbiol Infect Dis 2005; 52: 265-73.
32. Woods GL, Knapp CC, Washington JA 2nd. Relationship between cefamandole and cefuroxime activity against oxacillin-resistant Staphylococcus epidermidis and oxacillin resistance phenotype. Antimicrob Agents Chemother 1987; 31: 1332-7.
33. Fukasawa M, Noguchi H, Okuda T, Komatsu T, Yano K. In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity. Antimicrob Agents Chemother 1983; 23: 195-200.
34. Martínez-Martínez L, Pascual A, Bernard K, Suárez AI. Antimicrobial susceptibility pattern of Corynebacterium striatum. Antimicrob Agents Chemother 1996; 40: 2671-2.
35. von Eiff C, Herrmann M, Peters G. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Agents Chemother 1995; 39: 268-70.
36. Wise R, Andrews JM, Brenwald N. In vitro activity of the tricyclic beta-lactam GV104326. Antimicrob Agents Chemother 1996; 40: 1248-53.
37. Ling TK, Liu EY, Cheng AF. A 13-year study of antimicrobial susceptibility of common gram-negative bacteria isolated form the bloodstream in a teaching hospital. Chemotherapy 2001; 47: 29-38.
38. Seal D, Reischl U, Behr A etal. Laboratory diagnosis of endophthalmitis: comparison of microbiology and molecular methods in the European Society of Cataract & Refractive Surgeons multicenter study and susceptibility testing. J Cataract Refract Surg 2008; 34: 1439-50.
39. Espiritu CRG, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007; 33: 63-8.
40. Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery performed over 10years. J Cataract Refract Surg 2008; 34: 1114-20.
41. Davson H. Physiology of the Eye, 5th edn. London: Macmillan, 1990.
42. Montan PG, Wejde G, Setterquist H, Rylander M, Zetterström C. Prophylactic intracameral cefuroxime - evaluation of safety and safety in cataract surgery. J Cataract Refract Surg 2002; 28: 982-7.
43. Cunha-Vaz JG. The blood-ocular barrier: past, present, and future. Doc Ophthalmol 1997; 93: 149-57.
44. Sundelin K, Seal D, Gardner S etal. Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients. Acta Ophthalmol 2008; 87: 160-5.
45. Yoeruek E, Spitzer MS, Saygili O etal. Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal enothelial cells for intracameral use. J Cataract Refract Surg 2008; 34: 2139-45.